Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.
Roche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the rare muscle wasting disease spinal muscular atrophy (SMA) after support
